NasdaqGS:CRNXPharmaceuticals
Crinetics Starts Pediatric BALANCE CAH Trial As Valuation Gap Persists
Crinetics Pharmaceuticals has begun dosing pediatric patients in its Phase 2/3 BALANCE-CAH trial of atumelnant for classic congenital adrenal hyperplasia.
Atumelnant is described as a first in class oral ACTH receptor antagonist and is currently the only small molecule in late stage development targeting this mechanism.
The program received FDA Orphan Drug Designation for classic congenital adrenal hyperplasia, highlighting the focus on a rare pediatric condition with significant unmet...